Fig. 4: Acquired mutations and CNVs for 19 patients with acquired resistance to trastuzumab. | Oncogenesis

Fig. 4: Acquired mutations and CNVs for 19 patients with acquired resistance to trastuzumab.

From: Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy

Fig. 4

A Oncoprint for acquired mutations and CNVs across 19 patients with acquired resistance. Only alterations with ≥3 supporting samples were selected to be shown. B Forest plot for the hazard ratio of patients who acquired somatic mutations (Top) or CNVs (Bottom) vs. WT based on their PFS. A black box denotes the mean hazard ratio for each comparison to the reference. Error bars on forest plots represent the 95% confidence interval for each hazard ratio. Significant P values were shown in bold. Log-rank test was used to test for significance. C Survival curve of ERBB4 mutations based on PFS or D OS of patients. Kaplan–Meier curves for acquired FAT4 mutations were shown according to E PFS or F OS. WT wild type, CNV copy number variation.

Back to article page